youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
ARGX:NASDAQ
argenx SE - ADR
$869.72
arrow_upward
+5.34%(+44.11) 1D
$869.72
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 20, 4:00:01 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ARGX...
Open
$847.53
High
$881.10
Low
$843.51
Mkt. cap
54.34B
Avg. vol.
377.23K
Volume
536.44K
P/E ratio
33.04
52-wk high
$1,072.75
52-wk low
$661.85
EPS
$26.32
Beta
0.45
Shares outstanding
62.89M
No. of employees
2K
Open
$847.53
High
$881.10
Low
$843.51
Mkt. cap
54.34B
Avg. vol.
377.23K
Volume
536.44K
P/E ratio
33.04
52-wk high
$1,072.75
52-wk low
$661.85
EPS
$26.32
Beta
0.45
Shares outstanding
62.89M
No. of employees
2K
News stories
From web sources and news partners
Quiver Quantitative
·
4 hours ago
ARGX rises as investors revisit upcoming Phase 3 autoimmune myositis data presentation
TradingKey
·
5 hours ago
argenx SE Stock (ARGX) Moved Up by 5.99% on Oct 20: What Signal Does It Send?
marketscreener.com
·
5 hours ago
Argenx Shares 'Round Tripping,' Driven by Drug Development Updates, RBC Says
Investing.com
·
6 hours ago
Argenx shares see TD Cowen reiterate Buy on Q3 beat expectations
Profile
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
About argenx SE - ADR
Analyst ratings
Based on 21 analysts giving stock ratings to ARGX in the past 3 months
Strong buy
Buy
20
Hold
1
Sell
0
12-month forecast
Based on 21 Wall Street analysts offering 12 month price targets for ARGX in the last 3 months.
Highest
Current $869.72
$1,400.00 (+60.97%)
Average
$1,163.00 (+33.72%)
Lowest
$823.00 (-5.37%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Luca Issi RBC Capital | Buy | Reiterated | $1,025.00 | +17.9% | 10/20/2026 |
Derek Archila Wells Fargo | Buy | Reiterated | $1,356.00 | +55.9% | 10/14/2026 |
David Nierengarten Wedbush | Buy | Maintained | $1,130.00 | +29.9% | 10/13/2026 |
Leland Gershell Oppenheimer | Buy | Maintained | $1,038.00 | +19.3% | 10/12/2026 |
Tazeen Ahmad Bank of America Securities | Buy | Maintained | $1,157.00 | +33% | 10/13/2026 |
Sean Laaman Morgan Stanley | Buy | Maintained | $1,140.00 | +31.1% | 10/09/2026 |
Xian Deng UBS | Buy | Maintained | $1,400.00 | +61% | 10/08/2026 |
Gavin Clark-Gartner Evercore ISI | Buy | Maintained | $1,078.00 | +23.9% | 10/09/2026 |
Colleen M. Kusy Robert W. Baird | Hold | Reiterated | $823.00 | -5.4% | 10/09/2026 |
Thomas Smith Leerink Partners | Buy | Reiterated | $1,115.00 | +28.2% | 10/09/2026 |
Douglas Tsao H.C. Wainwright | Buy | Maintained | $1,202.00 | +38.2% | 10/08/2026 |
Alex Thompson CFA Stifel Nicolaus | Buy | Maintained | $1,282.00 | +47.4% | 10/08/2026 |
Unknown Analyst Jefferies | Buy | Maintained | $1,215.00 | +39.7% | 09/15/2026 |
Matt Phipps William Blair | Buy | Maintained | - | - | 09/02/2026 |
Danielle Brill Truist Financial | Buy | Maintained | $1,095.00 | +25.9% | 08/18/2026 |
Jason Butler Citizens JMP | Buy | Maintained | $1,200.00 | +38% | 08/18/2026 |
Samantha Semenkow Citi | Buy | Maintained | $1,301.00 | +49.6% | 08/18/2026 |
Yaron Werber TD Cowen | Buy | Reiterated | $1,353.00 | +55.6% | 08/17/2026 |
Allison Bratzel Piper Sandler | Buy | Maintained | $1,215.00 | +39.7% | 08/17/2026 |
Yatin Suneja Guggenheim | Buy | Initiated | $1,185.00 | +36.3% | 08/04/2026 |
Unknown Analyst Wedbush | Buy | Maintained | $1,050.00 | +20.7% | 07/28/2026 |
James Gordon CFA Barclays | Buy | Maintained | $950.00 | +9.2% | 07/24/2026 |
Myles Minter William Blair | Buy | Maintained | - | - | 06/24/2026 |
Unknown Analyst William O'Neil | Buy | Initiated | - | - | 06/08/2026 |
Rajan Sharma Goldman Sachs | Buy | Maintained | $910.00 | +4.6% | 02/26/2026 |
Next call in 39:27:24
Thu, Oct 22, 2:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$27.83
Revenue / Est. (USD)
- / 1.64B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.15B | 1.31B | 1.31B | 1.54B |
Cost of goods sold | 465.08M | 521.40M | 564.00M | 631.00M |
Cost of revenue | 465.08M | 521.40M | 564.00M | 631.00M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 336.29M | 429.62M | 355.00M | 417.00M |
Operating expense | 336.29M | 429.62M | 355.00M | 417.00M |
Total operating expenses | 801.37M | 951.02M | 919.00M | 1.05B |
Operating income | 349.97M | 359.56M | 394.00M | 493.00M |
Other non operating income | - | -907.00K | - | -1.00M |
EBT including unusual items | 386.05M | 403.29M | 426.00M | 531.00M |
EBT excluding unusual items | 386.05M | 391.71M | 426.00M | 531.00M |
Income tax expense | 41.80M | -129.66M | 60.00M | 59.00M |
Effective tax rate | 10.83% | -32.15% | 14.08% | 11.11% |
Other operating expenses | - | - | - | - |
Net income | 344.26M | 532.95M | 366.00M | 472.00M |
Net profit margin | 29.90% | 40.67% | 27.88% | 30.63% |
Earnings per share | 5.18 | 8.02 | 5.52 | 7.32 |
Interest and investment income | 42.70M | 44.95M | 44.00M | 48.00M |
Interest expense | -993.00K | - | -1.00M | -1.00M |
Net interest expenses | 41.71M | 44.95M | 43.00M | 47.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 350.35M | 361.38M | 395.82M | 501.50M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1